A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 546 participants.

Also called NCT06109311

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 546 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06109311
Other papers using this trial's data
  • Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial JAMA, 2026-08-04 DOI, PubMed 42251769, PMC13244277 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, China, Japan, Puerto Rico, Romania (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06109311. Randomized; double masking; primary purpose treatment. Start 2023-11-10 (actual); primary completion 2025-09-15 (actual). Results posted on 2026-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Acronym
ACHIEVE-5
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06109311
Content hash
d4032d4d21e52991601b240af02604813da67159fef86a0f3af42b9dfae33410